Craig H. Reynolds, MD | Authors

Clinical Efficacy of rhIL-11

September 01, 2000

Placebo-controlled clinical trials of recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy